Navigation Links
Cardiome To Release Second Quarter Results And Hold Conference Call
Date:8/11/2008

NASDAQ: CRME TSX: COM

VANCOUVER, Aug. 11 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced that it will report financial results for the second quarter ended June 30, 2008 on the afternoon of Tuesday, August 12, 2008. Cardiome will hold a teleconference call and webcast at 4:30pm Eastern (1:30pm Pacific) on that day to discuss the financial results and the recently-announced FDA action letter.

To access the conference call, please dial 416-641-6117 or 866-299-6655. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at http://www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through September 12, 2008. Please dial 416-695-5800 or 800-408-3053 and enter code 3268411 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at http://www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each ... goals for each and every seminar, session and class she offers. ... different brainwave tools which help energize creativity, focus mental functions, enhance athletic focus ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... On Thursday, February 16, 2017, ... at the closing bell, while the Dow Jones Industrial ... Moreover, five out of nine sectors ended Thursday,s trading ... sentiment, Stock-Callers.com assessed the following Medical Appliances & Equipment ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ...
(Date:2/16/2017)... 16, 2017 DaVita Inc. (NYSE: DVA ... December 31, 2016. Net income attributable to ... 2016 was $158 million, or $0.80 per share and $880 ... net income attributable to DaVita Inc. for the quarter and ... below, was $192 million, or $0.98 per share, and $789 ...
(Date:2/16/2017)...  Express Scripts (NASDAQ: ESRX ) was recognized today ... within the Health Care: Pharmacy and Other Services category. ... Most Admired Companies," said Tim Wentworth , CEO and President, ... of our 26,000 employees to make medicine more affordable and accessible ... ...
Breaking Medicine Technology: